Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:56 PM
Ignite Modification Date:
2025-12-24 @ 10:56 PM
NCT ID:
NCT03514069
Eligibility Criteria:
Inclusion Criteria:
Arm 1:
* Patients must have unmethylated MGMT supratentorial high-grade glioma (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed astro oligodendroglioma or glioblastoma).
Arm 2:
* Patients must have supratentorial methylated MGMT high-grade glioma (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed astro oligodendroglioma or glioblastoma).
Both:
* Patients must have MRI or CT with contrast within 28 days prior to starting treatment.
* Patients must have a Karnofsky performance status ≥ 70% (i.e. the patient must be able to care for himself/herself with occasional help from others).
* Patients must have adequate blood, kidney and liver function
* Patients must be able to provide written informed consent.
* Patients and their sexual partners must agree to avoid conception while on the study due to possible risks from experimental drugs. Women will need a negative pregnancy test to be on the study
* Patients may not have any other cancers except skin cancer and localized bladder, prostate, cervical, or breast cancer which were cured more than 3 years ago
Exclusion Criteria:
* Patients with other serious diseases
* Pregnant women
* Patients getting other cancer treatments
* Patients with other cancers except for localized skin cancer and localized bladder, prostate, cervical, or breast cancer which were cured more than 3 years ago
* Patients who have had repeat craniotomy for tumor therapy after receiving radiation therapy and temozolomide treatment.
* Patients who have previously received other treatments for their cancers
* Patient has previously taken ruxolitinib or is allergic to components of the study drug
* Use of blood thinners
* Human immunodeficiency virus (HIV) infection
* Active hepatitis B or C infection
* Heart diseases including abnormal electrocardiogram (EKG)
* Patients unwilling or unable to follow this protocol
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT03514069
Study Brief:
Protocol Section:
NCT03514069